MENU
NEWSLETTERS
MENU
SECTIONS
OTHER
CLASSIFIEDS
CONTACT US / FAQ
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Biogen Idec (NQ:BIIB)

197.19 -2.52 (-1.26%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jun 23, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Biogen Idec

< Previous 1 2
...
5 6 7 8 9 10 11 12 13
...
60 61 Next >
News headline image
Biogen to Highlight Scientific Progress Across Alzheimer’s Disease at the Alzheimer’s Association International Conference 2025
From Biogen Inc.
Via GlobeNewswire
News headline image
Biogen (BIIB) Stock Trades Down, Here Is Why
Shares of biotech company Biogen (NASDAQ:BIIB) fell 3.1% in the morning session after analysts at Truist downgraded the stock, citing concerns over the company's growth prospects and high-risk... 
Via StockStory
Topics Lawsuit
News headline image
What Does the Market Think About Biogen? ↗
 
Via Benzinga
News headline image
Biogen Bets Big On $2 Billion Expansion To Boost US Drug Manufacturing ↗
Biogen will invest an extra $2 billion to expand its RTP facilities, focusing on AI-driven manufacturing and late-stage clinical pipeline support. 
Via Benzinga
News headline image
What's going on in today's session: S&P500 movers ↗
Stay informed about the performance of the S&P500 index in the middle of the day on Monday. Uncover the top gainers and losers in today's session for valuable insights. 
Via Chartmill
News headline image
Biogen Announces $2 Billion Manufacturing Investment in North Carolina’s Research Triangle Park in Conjunction with its 30th Anniversary
From Biogen Inc.
Via GlobeNewswire
News headline image
Repligen, Bruker, Fortrea, Azenta, and Biogen Stocks Trade Down, What You Need To Know
A number of healthcare stocks fell in the afternoon session after several negative developments weighed on the sector. Weakness in managed care providers was a significant factor, with companies like... 
Via StockStory
Topics Lawsuit
News headline image
Is Bristol-Myers Squibb Still An Undervalued Biopharma Play? ↗
BofA cuts Bristol Myers' 2025 EPS and sales estimates slightly and flags medium-term pressure from generics, while maintaining a Neutral rating. 
Via Benzinga
News headline image
3 Low-Volatility Stocks in Hot Water
A stock with low volatility can be reassuring, but it doesn’t always mean strong long-term performance. Investors who prioritize stability may miss out on higher-reward opportunities elsewhere. 
Via StockStory
News headline image
Biogen and Stoke Therapeutics Announce Presentation of Data from Studies of Zorevunersen, an Investigational Medicine for Dravet syndrome, at the 16th European Paediatric Neurology Society (EPNS) Congress
From Biogen Inc.
Via GlobeNewswire
News headline image
Stoke Therapeutics and Biogen Announce Presentation of Data from Studies of Zorevunersen, an Investigational Medicine for Dravet syndrome, at the 16th European Paediatric Neurology Society (EPNS) Congress
From Stoke Therapeutics, Inc.
Via Business Wire
News headline image
What's Driving the Market Sentiment Around Biogen? ↗
 
Via Benzinga
News headline image
Biogen Shares Slip After $46M Research Charge Hits Quarterly Profit ↗
The company anticipates a research expense in Q2 associated with milestone and licensing payments, which will impact both GAAP and non-GAAP earnings per share. 
Via Stocktwits
News headline image
1 Value Stock with Exciting Potential and 2 to Approach with Caution
The low valuation multiples for value stocks provide a margin of safety that growth stocks rarely offer. However, the challenge lies in determining whether these cheap assets are genuinely undervalued... 
Via StockStory
News headline image
Biogen Initiates Phase 3 Study of Felzartamab for the Treatment of Primary Membranous Nephropathy
From Biogen Inc.
Via GlobeNewswire
News headline image
New Data for Nusinersen Underscore Biogen’s Commitment to Advancing Clinical Research to Improve Outcomes in SMA
From Biogen Inc.
Via GlobeNewswire
News headline image
Biogen-Ionis Partnered Drug Shows Benefit In Children With Spinal Muscular Atrophy Previously Treated With Novartis' Zolgensma ↗
Biogen's early-stage spinal muscular atrophy drug salanersen showed safety, motor improvements and 70% reduction in neurodegeneration markers after one-year dosing. 
Via Benzinga
News headline image
Nvidia To Rally Around 69%? Here Are 10 Top Analyst Forecasts For Wednesday ↗
 
Via Benzinga
News headline image
Biogen to Advance Investigational Spinal Muscular Atrophy Asset to Registrational Studies Based on Positive Interim Phase 1 Results
From Biogen Inc.
Via GlobeNewswire
News headline image
Can Biogen Outdo Its Own Spinal Muscular Atrophy Drug? ↗
Biogen is hoping to top its own spinal muscular atrophy treatment, Spinraza, with a next-generation version. 
Via Investor's Business Daily
News headline image
Sage Therapeutics Stock: JPMorgan Sees 8% Downside After Supernus Buyout Terms ↗
Analysts have also noted that the relatively low breakup fee may leave room for a competing offer, possibly from Biogen. 
Via Stocktwits
News headline image
Biogen Initiates Phase 3 Pediatric Study of Omaveloxolone for the Treatment of Friedreich Ataxia
From Biogen Inc.
Via GlobeNewswire
News headline image
Supernus Pharmaceuticals Gets Retail Excited Over $795M Acquisition Plan For Sage Therapeutics ↗
Under the terms of the deal, Supernus is looking to acquire Sage for a total consideration of $12 per share in cash. 
Via Stocktwits
Topics Government
News headline image
Supernus Pharma Acquires Maker Of Postpartum Depression Drug Zurzuvae In $795 Million Deal ↗
Supernus to acquire Sage Therapeutics for $795 million, gaining Zurzuvae and aiming for $200 million in annual cost synergies by expanding its CNS portfolio. 
Via Benzinga
News headline image
Beleaguered Sage Snapped Up In Deal Worth Up To $561 Million ↗
The deal expands Supernus Pharmaceuticals' presence in the nonpsychiatric space. 
Via Investor's Business Daily
Topics ETFs
News headline image
1 Profitable Stock with Exciting Potential and 2 to Avoid
A company with profits isn’t always a great investment. Some struggle to maintain growth, face looming threats, or fail to reinvest wisely, limiting their future potential. 
Via StockStory
News headline image
Biogen, UCB Take A Leap In Lupus With Promising Phase 3 Results ↗
UCB and Biogen's lupus candidate showed strong Phase 3 results, including fatigue improvement and higher remission versus standard care. 
Via Benzinga
News headline image
Demystifying Biogen: Insights From 11 Analyst Reviews ↗
 
Via Benzinga
News headline image
Dapirolizumab Pegol Phase 3 Data in SLE Presented at the Annual European Congress of Rheumatology (EULAR) Show Improvement in Fatigue and Reduction in Disease Activity
From Biogen Inc.
Via GlobeNewswire
News headline image
Entrada Therapeutics Appoints Maha Radhakrishnan, M.D., to its Board of Directors
From Entrada Therapeutics, Inc.
Via GlobeNewswire
< Previous 1 2
...
5 6 7 8 9 10 11 12 13
...
60 61 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story